Reckitt Benckiser Group (OTCMKTS:RBGLY – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday, Zacks.com reports. The firm presently has a $18.00 target price on the stock. Zacks Investment Research’s target price indicates a potential upside of 15.31% from the stock’s current price.
According to Zacks, “Reckitt Benckiser Group Plc engages in manufacturing and distributing household, toiletry, pharmaceutical and food products. The company offers antiseptic liquids, depilatory products, medicated sore throat products, condoms, cold/flu products, acne treatment products, analgesics and upper gastro-intestinal products, foot care and comfort footwear products, denture care and dry skin care products, fabric care products, surface care products and polishes/waxes. Reckitt Benckiser Group is based in Slough, the United Kingdom. “
A number of other analysts also recently weighed in on RBGLY. Barclays upped their target price on shares of Reckitt Benckiser Group from GBX 9,100 ($115.13) to GBX 9,300 ($117.66) in a research report on Tuesday, May 3rd. Societe Generale cut shares of Reckitt Benckiser Group from a “buy” rating to a “sell” rating in a research note on Wednesday, March 16th. Sanford C. Bernstein cut shares of Reckitt Benckiser Group from a “market perform” rating to an “underperform” rating in a research note on Monday, March 14th. Exane BNP Paribas upgraded shares of Reckitt Benckiser Group from an “underperform” rating to a “neutral” rating in a research note on Monday, March 14th. Finally, Jefferies Financial Group cut shares of Reckitt Benckiser Group from a “hold” rating to an “underperform” rating in a research note on Wednesday, March 23rd. Three research analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. Bas ed on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6,363.60.
OTCMKTS:RBGLY opened at $15.61 on Wednesday. The firm’s 50-day moving average price is $15.75 and its 200-day moving average price is $16.31. The company has a quick ratio of 0.44, a current ratio of 0.62 and a debt-to- equity ratio of 0.95. Reckitt Benckiser Group has a 1-year low of $14.40 and a 1-year high of $19.17.
Reckitt Benckiser Group Company Profile (Get Rating)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom, the United States, China, India, and internationally. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.
Get a free copy of the Zacks research report on Reckitt Benckiser Group (RBGLY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Reckitt Benckiser Group right now?
Before you consider Reckitt Benckiser Group, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Reckitt Benckiser Group wasn’t on the list.
While Reckitt Benckiser Group currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here